These ETFs House The Next Biotech Takeover Targets
August 26, 2013 at 07:44 AM EDT
Big news out of the biotechnology sector Monday as Amgen (NASDAQ: AMGN ) has finally reached an agreement to acquire Onyx Pharmaceuticals (NASDAQ: ONXX ) for $10.4 billion, or $125 per share. Amgen has long been pursuing Onyx so the former can bolster its lineup of cancer therapies. Related:
